CN105377282B - 环炔衍生化的糖 - Google Patents

环炔衍生化的糖 Download PDF

Info

Publication number
CN105377282B
CN105377282B CN201480012960.8A CN201480012960A CN105377282B CN 105377282 B CN105377282 B CN 105377282B CN 201480012960 A CN201480012960 A CN 201480012960A CN 105377282 B CN105377282 B CN 105377282B
Authority
CN
China
Prior art keywords
saccharide
conjugate
azide
group
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480012960.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377282A (zh
Inventor
R.阿达莫
F.伯蒂
胡琦颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN105377282A publication Critical patent/CN105377282A/zh
Application granted granted Critical
Publication of CN105377282B publication Critical patent/CN105377282B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480012960.8A 2013-01-15 2014-01-13 环炔衍生化的糖 Active CN105377282B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
GB1300707.5 2013-01-15
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (2)

Publication Number Publication Date
CN105377282A CN105377282A (zh) 2016-03-02
CN105377282B true CN105377282B (zh) 2020-07-17

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012960.8A Active CN105377282B (zh) 2013-01-15 2014-01-13 环炔衍生化的糖

Country Status (16)

Country Link
US (2) US11135300B2 (enExample)
EP (1) EP2945641B1 (enExample)
JP (3) JP6719209B2 (enExample)
CN (1) CN105377282B (enExample)
BR (1) BR112015016817B1 (enExample)
CA (1) CA2897348C (enExample)
CY (1) CY1122822T1 (enExample)
DK (1) DK2945641T3 (enExample)
ES (1) ES2774729T3 (enExample)
GB (1) GB201300707D0 (enExample)
HR (1) HRP20200351T1 (enExample)
LT (1) LT2945641T (enExample)
PL (1) PL2945641T3 (enExample)
PT (1) PT2945641T (enExample)
SI (1) SI2945641T1 (enExample)
WO (1) WO2014111344A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
SG11201807430WA (en) * 2016-03-04 2018-09-27 Euglena Co Ltd Antiviral agent and antiviral food
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US12050220B2 (en) 2018-02-05 2024-07-30 University Of Miyazaki Cell labeling agent and cell labeling kit
KR102784953B1 (ko) 2018-06-14 2025-03-21 모찌다 세이야쿠 가부시끼가이샤 신규 가교 알긴산
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
CA3221074A1 (en) * 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304765A (zh) * 2005-02-01 2008-11-12 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
CN101925366A (zh) * 2007-11-21 2010-12-22 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
WO2011136645A1 (en) * 2010-04-27 2011-11-03 Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen Fused cyclooctyne compounds and their use in metal-free click reactions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318117T3 (es) * 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
US7858101B2 (en) 2004-11-01 2010-12-28 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
EP2515914A4 (en) 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN103347862B (zh) 2010-09-27 2018-07-20 乔治亚大学研究基金公司 包含潜在的1,3-偶极-官能化合物的方法和由此制备的材料
US20120208722A1 (en) * 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
RU2014126482A (ru) * 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304765A (zh) * 2005-02-01 2008-11-12 诺华疫苗和诊断有限公司 链球菌荚膜糖的偶联
CN101925366A (zh) * 2007-11-21 2010-12-22 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
WO2011136645A1 (en) * 2010-04-27 2011-11-03 Stichting Katholieke Universiteit, More Particularly Radboud University Nijmegen Fused cyclooctyne compounds and their use in metal-free click reactions

Also Published As

Publication number Publication date
HRP20200351T1 (hr) 2020-06-12
BR112015016817B1 (pt) 2020-11-10
CN105377282A (zh) 2016-03-02
EP2945641B1 (en) 2020-01-01
US11135300B2 (en) 2021-10-05
JP2019073528A (ja) 2019-05-16
US12409231B2 (en) 2025-09-09
CY1122822T1 (el) 2021-05-05
US20210268116A1 (en) 2021-09-02
LT2945641T (lt) 2020-02-25
BR112015016817A8 (pt) 2019-10-29
JP2020114839A (ja) 2020-07-30
BR112015016817A2 (pt) 2017-07-11
EP2945641A1 (en) 2015-11-25
ES2774729T3 (es) 2020-07-22
GB201300707D0 (en) 2013-02-27
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15
PT2945641T (pt) 2020-03-26
JP7036854B2 (ja) 2022-03-15
CA2897348A1 (en) 2014-07-24
WO2014111344A1 (en) 2014-07-24
DK2945641T3 (da) 2020-03-09
US20160166704A1 (en) 2016-06-16
CA2897348C (en) 2022-09-27
JP2016506905A (ja) 2016-03-07
SI2945641T1 (sl) 2020-03-31

Similar Documents

Publication Publication Date Title
CN105377282B (zh) 环炔衍生化的糖
JP7268125B2 (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
JP5818826B2 (ja) 連鎖球菌性莢膜糖の複合
JP5590760B2 (ja) 低アセチル化または高アセチル化された髄膜炎菌の莢膜糖類
JP6093302B2 (ja) 免疫原性組成物
JP6266000B2 (ja) 免疫原性組成物
JP6170932B2 (ja) ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP5687405B2 (ja) 髄膜炎菌結合体ワクチン接種
KR20150060986A (ko) 비선형 사카라이드 컨주게이트
JP2016029103A (ja) 免疫原性組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant